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Abstract 
Background and Aim: Atrial fibrillation is the most common arrhythmia after coronary artery bypass grafting 
(CABG) and occurs in up to 30% of patients with heart failure. Mesenchymal stem cells (MSCs) can regenerate and 
improve cardiac function after tissue damage and are used in clinical trials. Due to the possible ability of MSCs to 
improve cardiac functions, in this work, we aimed to examine the probable association of the MSCs proliferation rate 
with the requirement for antiarrhythmic drugs in patients with severe left ventricular dysfunction after off-pump 
CABG.  
Methods: Bone marrow samples were obtained from the sternum of 30 patients who underwent off-pump CABG at 
Afshar Hospital and Seyed Al-Shohada Hospital. For calculating MSCs doubling time, the cells were counted after 4, 
7, and 14 days using trypan-blue color and a hemocytometer.  
Results: There were no significant differences between MSCs' doubling time and the patient's age and gender. The 
percentage of women patients who require antiarrhythmic medicine was significantly higher than men after surgery. 
Also, we demonstrated that the BMSCs doubling time in female patients who received antiarrhythmic drugs was less 
than that of male patients who received antiarrhythmic drugs, but these differences were not significant.  
Conclusion: Based on this research, we concluded that women patients who received antiarrhythmic drugs were 
significantly higher than men, but there was no apparent relevancy between MSCs doubling time and antiarrhythmic 
drugs requirement in patients with severe left ventricular dysfunction. 
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Introduction 
Today, despite many advances in treatment 
approaches, cardiac diseases are still responsible for 
millions of deaths worldwide, both in developed 
and developing societies (1). Severe left ventricular 
dysfunction is a condition in which the contractile 
strength of the myocardium is decreased, and the 
ejection fraction is reduced to less than 30% (2). 
Atrial fibrillation is the most common arrhythmia 
after coronary artery bypass grafting (CABG), 
which occurs in up to 30% of patients (3). This 
status is considered as unpleasant complications, 
including hemodynamic and thromboembolic 
problems and hospitalization period (4). Several 
antiarrhythmic drugs are commonly used to prevent 
atrial fibrillation after CABG. Administration of 
antiarrhythmic drugs reduced costs and 
hospitalization time and other complications (5). 
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The cause of atrial fibrillation is unknown, and the 
prevention and management of arrhythmia are 
crucial because it may lead to irreversible side 
effects. In the last two decades, novel regenerative 
medicine for cardiac tissue repair has been 
developed (6-8).  
Bone marrow-derived mesenchymal stem cells 
(BMSCs) are non-differentiated cells that can 
convert to many cell types of differentiated and 
active cells (9, 10). The findings of many studies 
have claimed that under suitable circumstances, 
MSCs can gain primary morphological features of 
cardiac cells (11, 12). Numerous in vivo studies 
have demonstrated that MSCs may be a promising 
therapeutic approach for the treatment of heart 
disorders (13). Due to the possible ability of MSCs 
to improve cardiac functions, we aimed to 
investigate the relationship between the 
proliferation rate of MSCs and taking 
antiarrhythmic drugs in patients with severe left 
ventricular dysfunction after off-pump CABG.  
Methods 
Study design and population  
Briefly, in this study, 30 patients with severe left 
ventricular dysfunction based on clinical findings, 
were randomly selected from patients referring to 
Seyed Al-Shohada hospital and Afshar hospital. 
The exclusion criteria included: patients with other 
heart diseases such as valvular heart disease, 
diabetes, and infectious diseases, and ejection 
fraction > 30. The study protocol was approved by 
the Ethics Committee of Shahid Sadoughi 
University of Medical Sciences.  
The patients filled in a written informed consent 
before study entry. All data were regarded as 
confidential. 
Culture of human bone marrow mesenchymal 
stem cells 
Bone marrow samples (1 mL) were obtained from 
sternum during off-pump CABG surgery from 
patients with severe left ventricular dysfunction. 
For isolating mesenchymal stem cells from bone 
marrow, the aspirated samples were diluted with 
minimum essential medium (αMEM). Samples 
were centrifuged, and then, cell pellets were 
resuspended in α MEM containing 20% fetal bovine 
serum (FBS) (Gibco, USA) and 1% 
streptomycin/penicillin (Gibco, USA), and cultured 
in 25 cm2 flasks at 37 °C in a humidified incubator 
containing 5% CO2.  
Doubling time of the BMSCs 
For evaluating the relationship between age, gender, 
and the taking antiarrhythmic drugs with MSC 
proliferation, population doubling times for all 
experimental groups were assessed. Briefly, 5000 
cells were seeded in 6-well plates. Cells for each 
well were trypsinized and counted in 4, 7, and 14 
days using trypan blue color and a hemocytometer. 
The counted cells' outcomes were plotted for the 
MSCs population, and doubling times were 
calculated from the log phase of the growth curve. 
Statistical analysis 
The GraphPad Prism Version 8 software (GraphPad 
Software, San Diego, CA, USA) was utilized to 
figure out data. All results are presented as mean ± 
standard deviation (SD). The two groups were 
compared using the unpaired t-test.  
Results 
The relationship between age and BMSCs 
doubling time 
Human bone marrow-derived MSCs did not differ 
in size and phenotype in all patients (Figure 1). In 
this study, 30 patients with left ventricular 
dysfunction were confirmed by the surgeon, which 
included 18 man and 12 women cases, with a 
median age of 60 years (range of 50–70 years). 
Figure 2 shows the relationship between the 
doubling time of BMSCs and the age of patients. 
There was no significant difference in the doubling 
time and age of patients (r2=0.0032).  
The relationship between gender and BMSCs 
doubling time  
Figure 3 displays the mean of BMSCs doubling 
time in male and female patients. There was no 
relevant discrepancy in the doubling time in males 
and females. The mean ± SD in the group of men 
was 230 ± 69, and in the group of women was 
202 ± 56.  
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Figure 1. Bone marrow-derived MSCs after extraction 
and culture. 
 
Figure 2. The relationship between the patients' age 
and BMSCs doubling time. 
The association between taking antiarrhythmic 
medication and BMSCs doubling time.  
Figure 4A illustrates that among 18 male patients in 
this study, two patients required antiarrhythmic 
drugs after surgery, while five female patients 
required antiarrhythmic drugs after surgery. 
Therefore, the percentage of women in 
antiarrhythmic drug requirements was significantly 
higher than men after surgery. Figure 4B possesses 
that the mean of BMSCs doubling time in female 
patients (207 ± 72) who received antiarrhythmic 
medication was less than that of male patients 
(283 ± 159) who received antiarrhythmic 
medication, but the difference was not substantial. 
Also, there was no disparity in BMSCs doubling 
time in man (224 ± 58) and women (198 ± 48) 
patients who did not receive medication.  
 
Figure 3. The relationship between gender of patients 
and BMSCs doubling time. 
 
Figure 4A. The relationship between antiarrhythmic 
drug requirements in male and female patients. 
 
Figure 4B. The relationship between MSCs and 
antiarrhythmic drugs taking in in male and female 
patients. 
Discussion 
Based on our results, the percentage of women who 
need antiarrhythmic drugs was significantly higher 
than men after surgery. Our data showed that the 
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doubling time of BMSCs in female patients who 
received antiarrhythmic medications was less than 
that of male patients, but these differences were not 
substantial.  
Today, despite noticeable advances in medical 
science, the prevalence of the cardiac disease is 
increasing globally (14, 15). Severe left ventricular 
failure after MI, a circumstance in which the 
reduction in blood flow and the reduction of oxygen 
delivery to the ventricular myocardium can cause 
the pump function failure and arrhythmia (16-18). 
Therefore, new therapeutic approaches for the 
treatment of heart failure should aim at reducing 
arrhythmia as well as improving hemodynamic 
function. Mesenchymal stem cell therapy is a 
promising option to improve cardiac function after 
MI (19, 20). However, some studies have shown 
that the injection of MSCs into infarcted 
myocardium increases the risk of arrhythmias. In 
2011, Deguo Wang et al. reported that MSCs 
injection ameliorates the inducibility of ventricular 
arrhythmias after myocardial infarction in rats (21). 
In contrast, some studies have recently reported that 
MSC therapy after acute MI related to reducing 
arrhythmias (22-24). Therefore, whether MSCs 
therapy causes the risk of arrhythmia is still vague. 
In the present study, two male patients and five 
female patients required antiarrhythmic drugs after 
surgery. The mean ± SD of doubling time of 
BMSCs in female patients who received 
antiarrhythmic drugs was less than that of male 
patients who received antiarrhythmic drugs, but the 
difference was not significant. A large number of 
studies have concluded that the ability of MSCs 
differentiation decreased with increasing age. 
However, some studies have shown that increasing 
age has nothing to do with the ability of MSCs 
differentiation (25). In 2011, Asumda et al. 
examined the relationship in age changes and MSCs 
in rats. They reported that with increasing age, the 
ability of MSCs differentiation was decreased (26). 
In our study, there was no significant relationship 
between the BMSCs doubling time and the patients' 
age. In female patients, the doubling time became 
longer with increasing age, but this doubling time 
was not remarkable due to the distribution of data 
and the number of patients. This decrement in the 
proliferation rate or increase of doubling time can 
be related to the decrease in telomere length and the 
activity of telomerase enzyme.  
Conclusion 
The results of the present study showed that there 
was not a clear relationship between the rate of 
MSCs proliferation and patients' age and gender 
after CABG. Based on the present research 
conclusion, the doubling time of bone marrow-
derived MSCs in female patients who received 
antiarrhythmic drugs was less than that of male 
patients with the same situations, but these 
differences were not significant. This insignificancy 
may be due to our small number of patients, and it 
is suggested that the present study be performed on 
a larger scale.  
Conflict of Interest 
The authors declared that they have no conflict of 
interest. 
Acknowledgment 
Not to declare. 
Funding/Support  
The authors declared that there is no financial 
support for this work.  
Ethics 
The study protocol was approved by the Ethics 
Committee of Shahid Sadoughi University of 
Medical Sciences with this code 
(IR.SSU.MEDICINE.REC.1397.199). 
References 
1. Savarese G, Lund LH. Global public health burden of 
heart failure. Cardiac failure review. 2017;3(1):7. 
2. Borlaug BA. The pathophysiology of heart failure with 
preserved ejection fraction. Nature Reviews Cardiology. 
2014;11(9):507. 
3. Rahman F, Kwan GF, Benjamin EJ. Global 
epidemiology of atrial fibrillation. Nature Reviews 
Cardiology. 2014;11(11):639. 
4. Simmers MB, Cole BK, Ogletree ML, Chen Z, Xu Y, 
Kong L-j, et al. Hemodynamics associated with atrial 
fibrillation directly alters thrombotic potential of 
endothelial cells. Thrombosis research. 2016;143:34-9. 
Association between Bone Marrow Mesenchymal Stem Cell …                                                    Esmailidehaj M, et al. 
Archives of Medical Laboratory Sciences; Volume 6, 2020 (Continuous Volume)  5 
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License 
5. Erdil N, Gedik E, Donmez K, Erdil F, Aldemir M, 
Battaloglu B, et al. Predictors of postoperative atrial 
fibrillation after on-pump coronary artery bypass 
grafting: is duration of mechanical ventilation time a risk 
factor? Annals of Thoracic and Cardiovascular Surgery. 
2014;20(2):135-42. 
6. Laksman Z, Wauchop M, Lin E, Protze S, Lee J, Yang 
W, et al. Modeling atrial fibrillation using human 
embryonic stem cell-derived atrial tissue. Scientific 
reports. 2017;7(1):1-11. 
7. Fisher SA, Doree C, Mathur A, Taggart DP, 
Martin‐Rendon E. Stem cell therapy for chronic 
ischaemic heart disease and congestive heart failure. 
Cochrane Database of Systematic Reviews. 2016(12). 
8. Abazari O, Divsalar A, Ghobadi R. Inhibitory effects 
of oxali-Platin as a chemotherapeutic drug on the 
function and structure of bovine liver catalase. Journal of 
Biomolecular Structure and Dynamics. 2019:1-7. 
9. Caplan AI. Mesenchymal stem cells: time to change 
the name! Stem cells translational medicine. 
2017;6(6):1445-51. 
10. Shafaei Z, Abazari O, Divsalar A, Ghalandari B, 
Poursoleiman A, Saboury AA, et al. Effect of a 
Synthesized Amyl-Glycine1, 10-Phenanthroline Platinum 
Nitrate on Structure and Stability of Human Blood 
Carrier Protein, Albumin: Spectroscopic and Modeling 
Approaches. Journal of fluorescence. 2017;27(5):1829-
38. 
11. Guo X, Bai Y, Zhang L, Zhang B, Zagidullin N, 
Carvalho K, et al. Cardiomyocyte differentiation of 
mesenchymal stem cells from bone marrow: new 
regulators and its implications. Stem cell research & 
therapy. 2018;9(1):44. 
12. Abazari O, Divsalar A, Ghobadi R. Inhibitory effects 
of oxali-Platin as a chemotherapeutic drug on the 
function and structure of bovine liver catalase. Journal of 
Biomolecular Structure and Dynamics. 2020;38(2):609-
15. 
13. Ward MR, Abadeh A, Connelly KA. Concise review: 
rational use of mesenchymal stem cells in the treatment 
of ischemic heart disease. Stem cells translational 
medicine. 2018;7(7):543-50. 
14. Rossignol P, Hernandez AF, Solomon SD, Zannad F. 
Heart failure drug treatment. The Lancet. 
2019;393(10175):1034-44. 
15. Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam 
M, Ghalandari B, Saboury AA. Probing the biological 
evaluations of a new designed Pt (II) complex using 
spectroscopic and theoretical approaches: Human 
hemoglobin as a target. Journal of Biomolecular 
Structure and Dynamics. 2016;34(5):1123-31. 
16. Smith ED, Tome J, Mcgrath R, Kumar S, Concannon 
M, Day SM, et al. Exercise hemodynamics in 
hypertrophic cardiomyopathy identify risk of incident 
heart failure but not ventricular arrhythmias or sudden 
cardiac death. International journal of cardiology. 
2019;274:226-31. 
17. Hemmeryckx B, Feng Y, Frederix L, Lox M, Trenson 
S, Vreeken R, et al. Evaluation of cardiac arrhythmic 
risks using a rabbit model of left ventricular systolic 
dysfunction. European journal of pharmacology. 
2018;832:145-55. 
18. Asadi A, Nezhad DY, Javazm AR, Khanicheragh P, 
Mashouri L, Shakeri F, et al. In vitro Effects of Curcumin 
on Transforming Growth Factor-β-mediated Non-Smad 
Signaling Pathway, Oxidative Stress, and 
Pro‐inflammatory Cytokines Production with Human 
Vascular Smooth Muscle Cells. Iranian Journal of 
Allergy, Asthma and Immunology. 2019:1-10. 
19. Yu H, Zhang N, Zhu J, Ma Q, Zhao Y, Wang Y, et al. 
Exosomes derived from human umbilical cord MSCs 
rejuvenate aged MSCs and enhance their functions for 
myocardial repair. 2020. 
20. Abazari O, Shafaei Z, Divsalar A, Eslami-Moghadam 
M, Ghalandari B, Saboury AA, et al. Interaction of the 
synthesized anticancer compound of the methyl-glycine 
1, 10-phenanthroline platinum nitrate with human serum 
albumin and human hemoglobin proteins by spectroscopy 
methods and molecular docking. Journal of the Iranian 
Chemical Society. 2020:1-14. 
21. Wang D, Zhang F, Shen W, Chen M, Yang B, Zhang 
Y, et al. Mesenchymal stem cell injection ameliorates the 
inducibility of ventricular arrhythmias after myocardial 
infarction in rats. International journal of cardiology. 
2011;152(3):314-20. 
22. Hare JM, Traverse JH, Henry TD, Dib N, Strumpf 
RK, Schulman SP, et al. A randomized, double-blind, 
placebo-controlled, dose-escalation study of intravenous 
adult human mesenchymal stem cells (prochymal) after 
acute myocardial infarction. Journal of the American 
College of Cardiology. 2009;54(24):2277-86. 
23. Mills WR, Mal N, Kiedrowski MJ, Unger R, Forudi 
F, Popovic ZB, et al. Stem cell therapy enhances 
electrical viability in myocardial infarction. Journal of 
molecular and cellular cardiology. 2007;42(2):304-14. 
24. Abbasi M, Abazari OO. Probing the Biological 
evaluations of a new designed Palladium (II) complex 
using spectroscopic and theoretical approaches: Human 
Hemoglobin as a Target. Archives of Medical Laboratory 
Sciences. 2018;3(3). 
25. Lin H, Sohn J, Shen H, Langhans MT, Tuan RS. 
Bone marrow mesenchymal stem cells: Aging and tissue 
engineering applications to enhance bone healing. 
Biomaterials. 2019;203:96-110. 
26. Asumda FZ, Chase PB. Age-related changes in rat 
bone-marrow mesenchymal stem cell plasticity. BMC 
cell biology. 2011;12(1):44.  
 
